Key Presentations on Hereditary Angioedema From AAAAI 2021

William R. Lumry, MD


March 22, 2021

Dr William Lumry reviews several key studies on acute hereditary angioedema (HAE) presented at the 2021 American Academy of Allergy, Asthma & Immunology virtual meeting.

Dr Lumry highlights updated results of the phase 3 APeX-2 trial, which led to the approval of the oral agent berotralstat for the treatment of HAE.

Data from the trial found that whether at baseline patients had a high-attack frequency or a relatively low-attack frequency, they achieved, on average, a 50% decrease in attack rates with the approved 150-mg dose, taken once daily. Prior prophylaxis did not affect the response rate.

Dr Lumry also reviewed a series of abstracts that took a deep dive into the open-label extension of the HELP study, which examined the efficacy and safety of lanadelumab, an injectable plasma kallikrein inhibitor. Efficacy and safety were unaffected by the number of attacks a patient had per month (one or fewer, or three or more).

In a late-breaking abstract, Dr Lumry reviewed the results of a study assessing a novel and potent bradykinin B2 receptor antagonist that is delivered orally.

Peak plasma levels after dosing were achieved within 30-60 minutes of taking the drug. Whether taken during fasting or after a high-calorie or standard breakfast, the drug achieved adequate plasma concentrations.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.